Literature DB >> 2766224

The prevalence of human T-cell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan.

S Hanada1, T Uematsu, M Iwahashi, K Nomura, A Utsunomiya, M Kodama, K Ishibashi, A Terada, T Saito, T Makino.   

Abstract

In order to clarify the prevalence of human T-cell leukemia virus type I (HTLV-I) infection in the Kagoshima district, Japan, a highly endemic area for HTLV-I, antibodies for HTLV-I (anti-HTLV-I) were examined in the sera of 6167 from healthy residents and patients with various hematologic and nonhematologic diseases. In healthy residents, including blood donors, the prevalence of anti-HTLV-I was 11.9% (562/4741 persons). The prevalence increased with age, and was significantly higher in in females than in males (P less than 0.01). The prevalence of anti-HTLV-I in blood donors was 8.5%. In In hematologic diseases, the prevalence of anti-HTLV-I was 98.3% in ATL, 28.9% in lymphoproliferative disorders except ATL, and 10.6% in myeloproliferative disorders. In nonhematologic diseases, the prevalence of anti-HTLV-I was shown to be 29.5% in pulmonary tuberculosis, 25.8% in leprosy, 33.8% in chronic renal failure (CRF), 21.9% in autoimmune diseases, and 47.8% in strongyloidiasis. The various diseases except myeloproliferative disorders had significantly higher prevalence of anti-HTLV-I than healthy residents (P less than 0.01 or 0.05). For autoimmune diseases, the prevalence of anti-HTLV-I in patients with blood transfusion (55.6%) was higher than in those without blood transfusion (8.7%), and healthy residents. In hemodialysis patients with CRF who had received blood transfusions the prevalence of anti-HTLV-I increased with the number of blood transfusions. Therefore, HTLV-I transmission via blood transfusion would partially explain these high prevalence of anti-HTLV-I. However, the prevalence of anti-HTLV-I in hemodialysis patients with CRF was statistically higher than that in healthy residents, regardless of blood transfusion (P less than 0.01). Furthermore, hemodialysis patients showed significantly higher prevalence of anti-HTLV-I than healthy residents, even at a younger age. Patients with pulmonary tuberculosis and leprosy showed the same results as hemodialysis patients. These results suggest that possibility that HTLV-I infection has some relation not only to ATL but also to other diseases. Therefore, it seems very important to halt the spread of HTLV-I transmission as soon as possible.

Entities:  

Mesh:

Year:  1989        PMID: 2766224     DOI: 10.1002/1097-0142(19890915)64:6<1290::aid-cncr2820640620>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Pancreatic tumor formed by infiltration of adult T-cell leukemia cells.

Authors:  K Mizumoto; N Suehara; J Ohuchida; H Kitada; G Naritomi; Y Ogawa; K Ohshima; K Sueishi; M Tanaka
Journal:  Int J Pancreatol       Date:  1997-06

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: active principles from Physalis pruinosa and structure-activity relationships with withanolides.

Authors:  Daisuke Nakano; Kenji Ishitsuka; Takahiro Hatsuse; Ryota Tsuchihashi; Masafumi Okawa; Hikaru Okabe; Kazuo Tamura; Junei Kinjo
Journal:  J Nat Med       Date:  2011-05-14       Impact factor: 2.343

4.  Strongyloidiasis.

Authors:  R G Shidrawi; D Westaby
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

Review 5.  Clinicopathological features of cryptococcal lymphadenitis and a review of literature.

Authors:  Keisuke Kawamoto; Hiroaki Miyoshi; Takaharu Suzuki; Reiji Muto; Kyohei Yamada; Eriko Yanagida; Mayuko Koshino; Yuya Sasaki; Jun Takizawa; Hirohito Sone; Yasuo Sugita; Masao Seto; Koichi Ohshima
Journal:  J Clin Exp Hematop       Date:  2017-06-08

6.  Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

Authors:  I Best; V Adaui; K Verdonck; E González; M Tipismana; D Clark; E Gotuzzo; G Vanham
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.

Authors:  Vanessa Adaui; Kristien Verdonck; Iván Best; Elsa González; Martín Tipismana; Jorge Arévalo; Guido Vanham; Miguel Campos; Mirko Zimic; Eduardo Gotuzzo
Journal:  J Neurovirol       Date:  2006-12       Impact factor: 2.643

8.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru.

Authors:  K Verdonck; E González; W Schrooten; G Vanham; E Gotuzzo
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

10.  Interactions between inflammatory gene polymorphisms and HTLV-I infection for total death, incidence of cancer, and atherosclerosis-related diseases among the Japanese population.

Authors:  Tara Sefanya Kairupan; Rie Ibusuki; Motahare Kheradmand; Yasuko Sagara; Eva Mariane Mantjoro; Yora Nindita; Hideshi Niimura; Kazuyo Kuwabara; Shin Ogawa; Noriko Tsumematsu-Nakahata; Yasuhito Nerome; Tetsuhiro Owaki; Toshifumi Matsushita; Shigeho Maenohara; Kazunari Yamaguchi; Toshiro Takezaki
Journal:  J Epidemiol       Date:  2017-05-30       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.